Aptuit Announces Acquisition of Exquiron Biotech AG

Expands capabilities in discovery to include high throughput screening and other early discovery services 

GREENWICH, CT, April 21, 2016 /CNW/ - Aptuit, LLC today announced that it has acquired Exquiron Biotech AG to meet customer demand for fully integrated outsourced discovery services. Exquiron is a leading specialist Contract Research Organization dedicated to early phase drug discovery solutions.

(Logo: http://photos.prnewswire.com/prnh/20150709/234432LOGO )

Located near Basel, Switzerland, Exquiron offers industry leading expertise in assay development for hit finding and profiling purposes, high throughput screening, selectivity testing and hit characterization. These services are complemented by an extensive library collection of lead like compounds, as well as deep scientific knowledge in compound selection and Structure Activity Relationship (SAR) expansion across a broad range of targets in multiple therapeutic areas.  

Dr. Jonathan Goldman, Chief Executive Officer of Aptuit stated, "Aptuit specializes in the discovery of small molecules across a wide range of therapeutic areas including neuroscience, oncology, infectious disease, inflammation, respiratory and others. The acquisition of Exquiron broadens our scientific excellence in advanced integrated discovery by incorporating capabilities in early discovery. In particular, we are thrilled to enhance our hit identification, validation, and expansion services. We can now offer uninterrupted and very high quality delivery of a research program from target to high quality candidate nomination. We expect our customers to benefit from improved probability of candidate nomination, with reductions in time and cost.

Customers value our unique capabilities in integrated discovery and integrated development. We are delighted to combine our core scientific expertise in discovery with the early discovery capabilities of our Exquiron colleagues."

Dr. Goldman explained that Aptuit's best in class integrated discovery solutions are unique in the marketplace.  

"Our company is experiencing increased demand for integrated services from gene up to candidate nomination, and from candidate to IND. We are delighted to respond by expanding our capabilities".

Dr. Stephan Fasler, CEO and founder of Exquiron added, "We are excited to join Aptuit, a highly respected leader in the discovery and development CRO sector. Our customers can now combine our expertise in assay development and high throughput screening with the ability to translate seamlessly to candidate nomination and IND filing. Exquiron and Aptuit share a culture and commitment to scientific excellence, making this a very good fit."

About Aptuit, LLC

Aptuit, LLC provides the most complete set of integrated early discovery to mid-phase drug development services in the pharmaceutical industry including Drug Design & Discovery, API Development and Manufacture, Solid State Chemistry, CMC, Preclinical and IND enabling GLP/GMP programs. Fully integrated drug discovery & development services are available from our facilities in the UK, Italy, and now Switzerland. Aptuit, LLC is partnered with Welsh, Carson, and Anderson & Stowe, one of the world's leading private equity investors.

For more information, please visit http://www.aptuit.com.

About Exquiron Biotech AG

Exquiron was founded in 2013 and is dedicated to state-of-the-art hit identification and validation services for its customers. With a combined team track record of over 60 years in early stage drug discovery and a high level of expertise and flexibility, they help their customers advance their programs and generate added value in the areas of pharmaceutical drug discovery and nutraceuticals.

For more information, please visit http://www.exquiron.com

SOURCE Aptuit LLC